AOD-9604

Assumed mechanism: AOD-9604 mimics the lipolytic C-terminal region of human growth hormone, stimulating fat breakdown (lipolysis) and inhibiting fat formation (lipogenesis) in adipocytes, proposed to act partly through beta-3 adrenergic signaling (cAMP -> protein kinase A -> hormone-sensitive lipase) rather than the GH receptor, which is why it does not raise IGF-1 or impair glucose in trials. This is well supported in rodent fat tissue; whether it produces clinically meaningful lipolysis in humans is exactly what the failed pivotal trial casts doubt on. Not an approved drug, so the mechanism remains "assumed/theoretical" in terms of real-world fat-loss benefit.

Result tags show how each trial came out. The letter counts every randomized trial, including ones that failed, because it measures how far testing got.

Adverse events

In the ~900-subject human safety dataset, treatment-related adverse events were mild and indistinguishable from placebo, most commonly mild headache and gastrointestinal symptoms. No serious adverse events were attributed to the drug; the handful of SAEs recorded (mostly skin cancers in an older obese cohort) were judged unrelated to treatment. No treatment-related withdrawals. This is an unusually clean human AE profile for this class.

Contraindications

No formal contraindication labeling exists because it is not an approved drug. Prudent avoidance applies in pregnancy/breastfeeding and in active or recent cancer (it is a GH-derived fragment, even if it does not raise IGF-1, and the trial population's skin-cancer cases warrant caution in those with malignancy history). Athletes subject to drug testing must avoid it entirely, it is WADA-prohibited (S2) and detectable. As of October 2026 it is not on the 503A bulks list and cannot lawfully be compounded.

Theoretical concerns

Designed specifically to avoid GH's downsides: across human trials it did NOT raise IGF-1 and did NOT impair glucose tolerance, which is the central safety claim and appears to hold. The main theoretical concerns for a peptide fragment like this are immunogenicity (antibody formation against a peptide fragment) and impurities from synthesis, concerns that apply especially to unregulated gray-market and compounded product of unknown purity rather than to the pharmaceutical-grade material used in trials.

What nobody knows yet

No human data beyond ~24 weeks, so long-term safety is genuinely unknown. Real-world gray-market product purity, dose accuracy, and immunogenicity are unverified. The injectable subcutaneous route favored by the community was not the primary route in the efficacy trials (which heavily used oral and IV), so the popular protocol is partly extrapolated. And the central efficacy question, does it produce meaningful fat loss in humans at all, is effectively answered "not reliably" by the failed pivotal trial.

What else could explain the result

Almost always run alongside a calorie deficit, increased training, and frequently other compounds (tirzepatide/semaglutide GLP-1 agonists, tesamorelin or CJC-1295/ipamorelin GH secretagogues, MOTS-c, stimulant fat-burners). Any fat loss is extremely hard to attribute to AOD-9604 specifically, especially given the small effect size seen even in the positive trial, and the pivotal trial's failure suggests most attributed results are diet, training, or co-administered drugs.

Is the vial what it says?

Cross-checked against PubMed (animal/in-vitro studies dominate; the key human paper is the 2013 pooled safety analysis), the published 12-week Phase 2 positive result, sponsor/press reporting of the failed pivotal Phase 2b and 2007 program termination, and the FDA PCAC December 2024 minutes recording the 12 to 0 vote against listing it for 503A compounding. Forum/vendor sources were read for sentiment only and discounted. The widely repeated "FDA GRAS status" is a sponsor self-affirmed GRAS determination for supplement use, NOT an FDA drug approval, these are routinely conflated by vendors and that distinction is load-bearing.

Half-life and storage

Half-life: Short. Plasma half-life is on the order of minutes after IV dosing (~3 minutes reported in pigs); functional/effective half-life is often cited around 30 minutes. Practically it clears the body quickly and limits accumulation.

Once mixed: Supplied as lyophilized powder; reconstitute with bacteriostatic (or sterile) water. Store lyophilized vials frozen (~ -20 C) or refrigerated; after reconstitution keep refrigerated at 2-8 C and use within roughly 28 days. Avoid repeated freeze-thaw cycles, heat, and vigorous shaking (swirl gently), and protect from light, peptides degrade with rough handling.

What people report

Volume of reports: faint. Little real-world record, or mostly noise.

Moderate chatter volume. AOD-9604 is a well-known "name" peptide in fat-loss circles and is widely sold, so it is discussed often. But that volume is dominated by vendor blogs, clinic marketing, and affiliate content rather than detailed independent user logs; genuine, specific first-person result reports are comparatively sparse.

Reports skew consistently underwhelming: users commonly describe subtle, slow effects at best, often indistinguishable from their diet and training, and frequently conclude it is the most "skippable" peptide in a stack. Few claim dramatic standalone fat loss. This low-key consensus actually aligns with the trial record (small effect, failed pivotal endpoint), which lends it some credibility even though it is anecdote.

Low-to-moderate. The loudest positive sources are vendors and clinics with a financial interest and are discounted. The more credible independent voices (experienced peptide users) tend to be lukewarm. Because almost everyone runs it inside a diet plus other compounds, even sincere positive reports have poor attribution. Net: the believable signal is faint.

• Common sentiment (anecdote, not proof): most users describe the fat-loss effect as subtle and slow at best, and many say it did little or nothing they could distinguish from their diet and training alone.
• It is frequently called the 'optional' or first-to-cut peptide in a stack, people running it with GLP-1 drugs or GH secretagogues often credit those instead.
• Tolerability reports are genuinely good: users rarely report meaningful side effects, with occasional mild injection-site reactions, mild headache, or transient flushing.
• A subset of users report feeling 'a bit leaner' or recovering faster from joint aches, but these are soft, subjective impressions consistent with placebo and concurrent dieting.

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: Human dosing began in Phase 1/2 trials run by Metabolic Pharmaceuticals (Monash University spin-out, Australia) starting around 2001; the published pooled human safety analysis (Stier et al., Journal of Endocrinology and Metabolism, 2013) covers six randomized, double-blind, placebo-controlled trials conducted 2001-2006 in roughly 900 obese adults. Unlike most peptides in this category, controlled human trials WERE completed, but the pivotal Phase 2b efficacy trial failed its primary endpoint and development was halted in 2007.

1. 1990sResearchers at Monash University (Australia) map GH's fat-reducing activity to a small C-terminal region (~residues 176-191), spinning out Metabolic Pharmaceuticals to develop a fragment drug.
2. ~2000-2001Preclinical metabolic and obese-mouse studies of the synthetic lipolytic fragment (AOD9604) published; first-in-human dosing begins.
3. 2001-2006Six randomized, double-blind, placebo-controlled human trials conducted in ~900 obese adults (IV and oral; doses from 0.25 mg up to tens of mg).
4. ~2004-2006A 12-week Phase 2b study in 300 obese adults is reported in a conference abstract (2005): more weight loss than placebo at every oral dose, largest at 1 mg, raising hopes for an oral anti-obesity drug.
5. 2007Pivotal Phase 2b trial fails its primary weight-loss endpoint; Metabolic Pharmaceuticals halts the formal drug-development program.
6. 2011-2013AOD-9604 self-affirmed as GRAS by its sponsor for use in supplements/foods (a company-determined status, NOT FDA approval); 2013 pooled human safety analysis published.
7. ~2010s-2020sRepurposed by clinics/compounders for fat loss and (on animal data) joint health; named on WADA's prohibited list (S2.3, growth hormone fragments).
8. Dec 4, 2024FDA Pharmacy Compounding Advisory Committee votes 12 to 0 that AOD-9604 NOT be placed on the 503A bulks list. It remains off the list.

• PubMed - AOD9604 (all literature; animal/in-vitro dominant)(Core literature search. Confirms human data is thin (2013 pooled safety paper) while most studies are rodent/in-vitro.)
• Stier et al. 2013 - Safety and tolerability of AOD9604 in humans (J Endocrinol Metab)(Stier et al., J Endocrinol Metab 2013: six randomized placebo-controlled trials; no IGF-1 effect, no glucose-tolerance harm, no serious adverse events attributed to drug. Authors are linked to the sponsor.)
• PubMed - AOD9604 obesity / weight loss(Human weight-loss study context: small positive 12-week study vs the failed larger pivotal trial.)
• PubMed - AOD-9604 Metabolic (Wilding, Curr Opin Investig Drugs 2004)(Short pipeline note; supports that the development program existed. ClinicalTrials.gov holds no AOD-9604 studies (checked 2026-10-12), so the failed pivotal trial rests on sponsor and trade-press reports.)
• FDA Pharmacy Compounding Advisory Committee, final summary minutes, Dec 4 2024(Records the 12 to 0 vote against placing AOD-9604 on the 503A bulks list. Not FDA-approved.)
• Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab 2013;3(1-2):7-15. doi 10.4021/jem157w; trial design also summarized in FDA PCAC briefing document, Nov 5 2024(dose table)
• Stier H, Vos E, Kenley D. J Endocrinol Metab 2013;3(1-2):7-15. doi 10.4021/jem157w. Efficacy abstract as summarized in FDA PCAC briefing document, Nov 5 2024 (Herd et al. 2005 abstract)(dose table)
• Stier H, Vos E, Kenley D. J Endocrinol Metab 2013;3(1-2):7-15. doi 10.4021/jem157w(dose table)
• Stier H, Vos E, Kenley D. J Endocrinol Metab 2013;3(1-2):7-15. doi 10.4021/jem157w(dose table)
• FDA Briefing Document, Pharmacy Compounding Advisory Committee, Dec 4 2024 meeting: Evaluation of AOD-9604-related bulk drug substances(dose table)